Key result
Intracellular Ca2+ signaling acts as a bilateral upstream regulator of pathways controlling both skeletal muscle hypertrophy and atrophy, presenting a potential therapeutic target for muscle mass.
Ca2+ signaling is a key upstream regulator of skeletal muscle plasticity, offering a potential therapeutic target for conditions involving muscle hypertrophy or atrophy.
Ca2+ signaling may link muscle hypertrophy and atrophy pathways; hypothesis-generating and requires clinical trials before any therapeutic consideration.
Skeletal muscle maintains an adequate volume that is commensurate with its surrounding environment. Although intracellular signaling molecules and pathways underlying the regulation of protein synthesis/degradation and subsequent muscle hypertrophy/atrophy are well studied, upstream regulators are largely unknown. In this review, we summarize the recent advances relating to the role of Ca2+ signaling as an upstream regulator of intracellular signaling pathways that regulate muscle plasticity, suggesting a new therapeutic target to control muscle mass.
No takes yet. Share an insight, caveat, or question.
Ito et al. (2015) conducted a review in Skeletal muscle hypertrophy and atrophy. Ca2+ signaling was evaluated. Intracellular Ca2+ signaling acts as a bilateral upstream regulator of pathways controlling both skeletal muscle hypertrophy and atrophy, presenting a potential therapeutic target for muscle mass.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: